Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

FDA Approves Remestemcel-L for Pediatric Steroid-Refractory Acute Graft-vs-Host Disease

December 18th 2024

The FDA has approved remestemcel-L-rknd for pediatric steroid-refractory acute graft-vs-host disease.

Factors That Influence Treatment Decisions in Later-Line CML

December 18th 2024

Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, discuss factors that influence later-line treatment choices in chronic myeloid leukemia.

Implications of the FDA Approval of Asciminib for Newly Diagnosed, Ph+ CP-CML

December 18th 2024

Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, on the implications of the FDA approval of asciminib in newly diagnosed CP-CML.

Orca-Q Leads to Low Rates of GVHD, Non-Relapse Mortality in High-Risk Hematologic Malignancies

December 16th 2024

Orca-Q led to low rates of graft-vs-host disease and non-relapse mortality in high-risk hematologic malignancies.

100-mg Bezuclastinib Improves Symptoms, Biomarkers in Non-Advanced Systemic Mastocytosis

December 13th 2024

Treatment with a 100-mg dose of bezuclastinib had a favorable safety and tolerability profile in patients with non-advanced systemic mastocytosis.

Iopofosine I 131 Is Efficacious, Tolerable in Heavily Pretreated R/R Waldenström Macroglobulinemia

December 12th 2024

Iopofosine I 131 demonstrated durable efficacy and tolerability in heavily pretreated relapsed/refractory Waldenström macroglobulinemia.

Risk Management Measures Improved Safety, Prevention, and Management of Ponatinib-Associated AEs in CML and AML

December 11th 2024

Select safety measures have improved the prevention and management of risks associated with ponatinib in ALL and CML over 10 years.

IO-202 Plus Azacitidine Elicits Responses in HMA-Naive Chronic Myelomonocytic Leukemia

December 11th 2024

IO-202 plus azacitidine elicited an ORR of 66.7% in patients with HMA-naive chronic myelomonocytic leukemia.

NFKB1 Haplotype Decreases Inflammation, Increases Response to Ropeginterferon Alfa-2b in PV and ET

December 11th 2024

NFKB1 rs230511 reduces inflammation and amplifies responses to ropeginterferon alfa-2b in polycythemia vera and essential thrombocythemia.

Tafasitamab Plus Lenalidomide/Rituximab Improves PFS in Relapsed/Refractory Follicular Lymphoma

December 10th 2024

Tafasitamab plus lenalidomide and rituximab improved median PFS vs lenalidomide and rituximab in patients with relapsed/refractory follicular lymphoma.

Dr Wang on Ziftomenib Plus Intensive Induction in Newly Diagnosed, NPM1+ or KMT2A+ AML

December 10th 2024

Eunice S. Wang, MD, on ziftomenib plus intensive induction in newly diagnosed, NPM1-mutated or KMT2A-rearranged acute myeloid leukemia.

BGB-16673 Demonstrates Initial Antitumor Activity, Tolerability in Select Relapsed/Refractory B-Cell Malignancies

December 10th 2024

BGB-16673 monotherapy showed early activity and a tolerable safety profile in relapsed/refractory Waldenström macroglobulinemia, CLL, and SLL.

Breaking the News in Myeloma, GVHD, and NHL, With Drs Rajkumar, Farhadfar, and Smith

December 10th 2024

S. Vincent Rajkumar, MD, of Mayo Clinic; Nosha Farhadfar, MD, of Methodist Physician Practices; and Sonali Smith, MD, of University of Chicago Medicine, sit down with Chandler Park, MD, FACP, to discuss the latest in multiple myeloma, graft-vs-host disease, and non-Hodgkin lymphoma, respectively, from the 2024 ASH Annual Meeting.

Zanubrutinib Reduces Long-Term Risk of Progression or Death by 71% in Newly Diagnosed CLL/SLL

December 9th 2024

Frontline treatment with zanubrutinib continued to improve PFS vs bendamustine plus rituximab at 5 years in patients with treatment-naive CLL/SLL.

Second-Generation BTK Inhibitors Exhibit Lower Incidence of Cardiac AEs in B-Cell Malignancies

December 9th 2024

Second-generation BTK inhibitors were associated with a significantly lower incidence of cardiac adverse effects in B-cell malignancies.

Uproleselan Plus Chemo Fails to Produce OS Benefit in Relapsed/Refractory AML

December 9th 2024

The addition of uproleselan to chemotherapy did not meet the primary OS end point of a phase 3 trial evaluating patients with relapsed/refractory AML.

Outpatient Lymphodepletion Before Brexu-Cel Remains Safe, Efficacious in Mantle Cell Lymphoma and Acute Lymphoblastic Leukemia

December 9th 2024

Outpatient lymphodepletion prior to brexu-cel was safe and generated comparable 60-day non-relapse mortality vs inpatient administration in B-ALL and MCL.

Zilovertamab Vedotin Plus R-CHP Yields 97.2% Overall CR Rate in DLBCL

December 9th 2024

Patients with treatment naive DLBCL experienced high response rates when treated with zilovertamab vedotin plus R-CHP and a RP2D dose of the agent was selected.

Liso-Cel Shows Broad Spectrum Activity in CIBMTR Cohort of Relapsed/Refractory LBCL

December 8th 2024

Liso-cel demonstrated safety and efficacy outcomes that were comparable to those in the pivotal TRANSFORM and PILOT trials in patients with relapsed/refractory large B-cell lymphoma.

Social Determinants of Health Correlate With Receipt of Allo-HSCT in AML

December 8th 2024

Social determinants of health have a more pronounced effect on mortality among patients with AML who did not receive transplant vs those who did.